Latest Content

Lunsumio plus Polivy Associated With Responses in MCL

September 9th 2025, 7:00pm

By Ashling Wahner

Article

For patients with relapsed/refractory mantle cell lymphoma Lunsumio plus Polivy was associated with durable responses.

Standing Up to Cancer with Lynch Syndrome

September 9th 2025, 4:55pm

By Georgia Hurst

Article

What does standing up to cancer mean to me? It means showing up for my life, even knowing that cancer is not a distant possibility but a biological reality.

Zidesamtinib Elicits Responses in ROS1-Positive NSCLC

September 9th 2025, 4:00pm

By Caroline Seymour

Article

Patients with advanced, pretreated ROS1-positive NSCLC treated with zidesamtinib saw an objective response rate of 44%.

Rybrevant Plus Lazcluze Associated with Survival Improvement in NSCLC

September 9th 2025, 3:11pm

By Alex Biese

Article

For some with previously untreated locally advanced or metastatic non-small cell lung cancer Rybrevant plus Lazcluze improved overall survival.

Suleika Jaouad on Why Self-Advocacy Matters for Patients With Cancer

September 9th 2025, 1:00pm

By Suleika Jaouad

Video

CURE spoke with the patient advocate and author of “Between Two Kingdoms” and “The Book of Alchemy.”

The Seasons of Cancer

September 8th 2025, 9:00pm

By Felicia Mitchell

Article

The symbolism of seasons helped me to put some challenges of my cancer journey into perspective.

What Patients With Lung Cancer Need to Know About KRAS G12C Mutations

September 8th 2025, 8:00pm

By Dr. Alexander Spira

Video

CURE spoke with Dr. Alexander Spira to learn what patients need to know about the KRAS G12C mutation and its treatment strategies.

Ivonescimab Plus Chemo Delays NSCLC Progression

September 8th 2025, 7:00pm

By Ashley Chan

Article

In patients with EGFR-mutated NSCLC ivonescimab plus chemotherapy was associated with significant progression-free survival.

Standing Up to Cancer on My Own Two Feet

September 8th 2025, 5:00pm

By Ronald Chin

Article

Thoughts on standing up to cancer through recovered mobility and by sharing my multiple myeloma journey.

FLAURA2 Shows Tagrisso Plus Chemo Boosts Survival in EGFR+ Lung Cancer

September 8th 2025, 4:00pm

By Dr. Eric K. Singhi

Video

Dr. Eric Singhi sat down with CURE to break down the findings from the phase 3 FLAURA2 study, presented at the 2025 IASLC World Conference on Lung Cancer.

FDA Grants Orphan Drug Designation to BA-101 in Glioblastoma

September 8th 2025, 3:02pm

By Alex Biese

Article

The FDA has granted orphan drug designation to the investigational therapy BA-101 for the treatment of patients with glioblastoma.

Ifinatamab Deruxtecan Shows Activity in Previously Treated ES-SCLC

September 8th 2025, 1:17pm

By Dr. Myung-Ju Ahn

Video

Dr. Myung-Ju Ahn shared notable data on ifinatamab deruxtecan for patients with previously treated extensive-stage small cell lung cancer.

Tagrisso With Chemotherapy Improves Survival in EGFR+ NSCLC

September 7th 2025, 6:00pm

By Kristi Rosa

Article

People with EGFR+ NSCLC whose disease spread outside the brain after treatment with Tagrisso lived longer when they kept taking Tagrisso along with chemo.

Iza-bren Plus Tagrisso May Offer a New Option for Advanced Lung Cancer

September 7th 2025, 2:00pm

By Jax DiEugenio

Article

A combination of Iza-bren and Tagrisso showed beneficial results as an initial treatment for advanced/metastatic EGFR-mutated non–small cell lung cancer.

Dispelling Myths and Raising Awareness of Lung Cancer Risk

September 6th 2025, 6:00pm

By Leah Phillips

Video

Never-smoker Leah Phillips, co-founder of the Young Lung Cancer Initiative, raises awareness that anyone with lungs can develop lung cancer.